Abstract
Multidrug resistance (MDR) is the reason cancer treatment fails to respond to standard drugs. This failure has led to a major public health crisis as about 50% of cancers treated with chemotherapeutic drugs become resistant to the same or related anticancer drugs. Studies have shown that almost all cancers can develop resistance during treatment hence the need to develop a novel therapeutic regime. Cancer drug resistance is a complex phenomenon linked to increased expression of drug efflux proteins. These proteins include, P-glycoprotein (P-gp), breast cancer resistance proteins (BCRP), multidrug resistance-associated proteins (MRP) among others that belong to the ATP-binding cassette (ABC) transporters. It has been reported that repeated or continuous drug treatment upregulates efflux protein activity which prevents the accumulation of drugs thus contributing to drug resistance...
D.Tech. (Biomedical Technology)